Navigation Links
Common gene variants increase risk of hypertension, may lead to new therapies
Date:2/15/2009

A new study has identified the first common gene variants associated with an increased incidence of hypertension a significant risk factor for heart attack, stroke and kidney failure. The report receiving early online release in the journal Nature Genetics identifies variants in genes for proteins involved with cardiovascular response to stress that also appear to influence blood pressure levels, an association previously seen in animals but not demonstrated in humans.

"It's well known that hypertension can run in families, and a few rare genetic syndromes that raise blood pressure have been identified. But the common genetic basis for the type of hypertension that affects a billion individuals around the world has been very difficult to establish," says Christopher Newton-Cheh, MD, MPH of the Massachusetts General Hospital (MGH) Center for Human Genetic Research and Cardiovascular Research Center, first author of the Nature Genetics report.

To search for hypertension-associated variants, the investigators focused on two genes called NPPA and NPPB that are involved in the production of atrial and B-type natriuretic peptides (ANP and BNP) proteins known to relax blood vessels and to be involved in the excretion of dietary sodium. Animals in which both copies of NPPA have been knocked out are hypertensive, and even those with a single functional copy will develop hypertension on a high-sodium diet.

The overall study involved analyzing genetic data from almost 30,000 individuals. The researchers first screened 1,700 participants in the Framingham Heart Study for 13 common variations called single-nucleotide polymorphisms (SNPs) in the NPPA and NPPB genes, looking for any correlation with levels of ANP and BNP. SNPs identified in that first stage were validated in three other study groups, including participants from Sweden and Finland; and variants associated with changes in natriuretic peptide levels were then tes
'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. New vaccine developed for preventing uncommon cold virus
2. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
3. Common soil mineral degrades the nearly indestructible prion
4. Scientists uncover evolutionary keys to common birth disorders
5. Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases
6. Common food additive found to increase risk and speed spread of lung cancer
7. Hairspray is linked to common genital birth defect, says study
8. GUMC researchers hone in on new strategy to treat common infection
9. First comprehensive genomic study of common cold reveals new treatment targets
10. Researchers identify Achilles heel of common childhood tumor
11. Study provides insight on a common heart rhythm disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... The American Physiological Society (APS; www.the-APS.org ) announced ... Fellowships to TanYa Gwathmey and Kesia Mathis. This is ... Gwathmey, an African-American, is a postdoctoral fellow in the ... University School of Medicine in Winston-Salem, N.C. There she ...
... previously-unreported callus hairs growing in the flesh of mature ... storage implications for commercial growers. To find out ... Mary Parker of the Institute of Food Research. Apples ... history and Fuji apples are particularly prized for their ...
... the launch of Bioscience Horizons, a unique peer-reviewed journal ... in the UK and Republic of Ireland. ... a collaboration between the universities of Leeds, Nottingham, Reading, ... to provide a forum for the brightest undergraduates in ...
Cached Biology News:APS names 2 minority outreach fellows 2APS names 2 minority outreach fellows 3Popular apple variety harbors unusual cell growth 2
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... DALLAS , July 30, 2015  With over 60,000 customers across the globe, ISN ... helps connect 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 ... ... ... Headquartered in Dallas, ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
(Date:7/30/2015)... ... , ... As part of its 2015 growth plan and as a follow up to the ... units, Whitehouse Laboratories is pleased to announce that it has begun construction on a new ... and will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... the University of Pennsylvania demonstrates a more consistent and ... has promising applications in a variety of fields, and ... Physics. As explained in a recently published study, ... graphene that is just a single atom thick over ...
... QUINCY, Mass., March 2, 2011 Myriant Technologies, ... of renewable bio-based chemicals, announces the addition of ... effective immediately.  Mr. Ferguson, 56, is the former ... global chemical company engaged in the manufacture and ...
... N.C., March 2, 2011 Cempra Pharmaceuticals Inc. today ... executive officer, will present at the Cowen and Company ... March 7, 2011, at The Boston Marriott Copley Place ... the company,s two leading antibiotic clinical programs, solithromycin for ...
Cached Biology Technology:Penn physicists develop scalable method for making graphene 2Penn physicists develop scalable method for making graphene 3Myriant Technologies, Inc. Announces J. Brian Ferguson to Join Advisory Board 2
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
...
Biology Products: